Readers Write: Funding cuts, American heroes, Christianity
Last week we learned that the funding for medical research is in jeopardy. President Donald Trump’s executive order to cut ...
Cupid’s Undie Run returns to Reno to raise awareness for neurofibromatosis
RENO, Nev. (KOLO) - Saturday, Feb. 22 hundreds of people in Reno will take to the streets in just their undies during Cupid’s Undie Run. The event raises awareness of neurofibromatosis (NF), a genetic ...
BioWorld8h
Springworks’ Gomekli wins priority FDA nod for NF1 neurofibromas
Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...
Spring Works shares rise on raised price target to $66
TD Cowen analysts increased their price target for Spring Works Therapeutics (NASDAQ:SWTX) shares to $66.00 from $63.00, while maintaining a "Buy" rating on the stock. The company's shares, currently ...
SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg
SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, ...
SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25
SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved GOMEKLI, a small molecule MEK inhibitor, ...
The American Journal of Managed Care15h
FDA Approves Mirdametinib for Neurofibromatosis Type 1 with Plexiform Neurofibromas
Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...
BioSpace17h
SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
GlobalData on MSN18h
FDA approves Gomekli as first neurofibromatosis drug for adults
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
US FDA approves SpringWorks' genetic disorder drug
The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...
FDA approves new genetic disorder drug
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of noncancerous tumors on ...
HRS: Cupid’s undie run, a blushing way to raise money for NF
PORTSMOUTH, Va. (WAVY) – In 2010, a group of enthusiastic supporters ran through the cold in Washington, D.C., dropping their pants to raise money for research to help end neurofibromatosis (NF), a ...